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Virus entry is a multistep process. It initiates when the virus
attaches to the host cell and ends when the viral contents reach
the cytosol. Genetically unrelated viruses can subvert analogous
subcellular mechanisms and use similar trafficking pathways for
successful entry. Antiviral strategies targeting early steps of
infection are therefore appealing, particularly when the probabil-
ity for successful interference through a common step is highest.
We describe here potent inhibitory effects on content release and
infection by chimeric vesicular stomatitis virus (VSV) containing
the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-
SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small-molecule
inhibitors of the main endosomal phosphatidylinositol-3-phos-
phate/phosphatidylinositol 5-kinase, PIKfyve. We also describe po-
tent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by
Apilimod. These results define tools for studying the intracellular
trafficking of pathogens elicited by inhibition of PIKfyve kinase
and suggest the potential for targeting this kinase in developing
small-molecule antivirals against SARS-CoV-2.
COVID-19 | SARS-CoV-2 | ZEBOV | APILIMOD | Vacuolin-1
Membrane-enveloped viruses deliver their contents to cellsvia envelope protein-catalyzed membrane fusion. Binding
of virus to specific host cell receptor(s) triggers membrane fu-
sion, which can occur directly at the plasma membrane or fol-
lowing endocytic uptake. Viruses that require endocytic uptake can
use different initial trafficking routes to reach the site of membrane
fusion. In endosomes, acidic pH serves to trigger conformational
rearrangements in the viral envelope proteins that catalyze mem-
brane fusion, as seen for influenza A virus and vesicular stomatitis
virus (VSV). For Zaire ebolavirus (ZEBOV), proteolytic pro-
cessing of the envelope protein by host cell proteases (1) is nec-
essary to expose the receptor binding domain prior to engagement
of Niemman−Pick disease type 1C (NPC1 or NPC Intracellular
Cholesterol Transporter 1)—the late endosomal−lysosomal re-
ceptor protein (2). Proteolytic processing is also required for severe
acute respiratory syndrome coronavirus (SARS-CoV) (3, 4), and
for the current pandemic SARS-CoV-2 (5). Lassa fever virus
(LASV) uses a different mechanism, binding alpha-dystroglycan at
the plasma membrane (6), for internalization with a subsequent
pH-regulated switch that leads to engagement of lysosomal-
associated membrane protein 1 for membrane fusion (7). Lym-
phocytic choriomeningitis virus (LCMV) also uses alpha-dystroglycan
(6) and is internalized in a manner that depends on endosomal
sorting complexes required for transport proteins (8), although it
remains unknown whether a second receptor is required.
A hallmark of the endolysosomal system is controlled dynamic
trafficking of vesicular carriers among its various subcompart-
ments. Phophoinositides are markers for defining the identity of
these subcompartments, because they are restricted in their dis-
tribution to specific intracellular membranes (reviewed in ref. 9).
Although it is one of the least abundant of the phosphoinositides
in cells, PI(3,5)P2 is particularly important for endomembrane
homeostasis. It is produced by PI-3P-5-kinase (PIKfyve), which
phosphorylates the D-5 position in phosphatidylinositol-3-phos-
phate (PI3P) to yield phosphatidylinositol 3,5-bisphosphate
(PI(3,5)P2) (10). First cloned as mammalian p235 (11), PIKfyve is
a 240-kDa class III lipid kinase, present on the cytosolic face of
endosomal membranes (12, 13) as part of a ternary complex with
the PI(3,5)P2 5-phosphatase Sac3 and ArPIKfyve (14).
Ablation of PIKfyve function by genetic (12, 15) or pharma-
cological means (16–20) causes endosomal swelling and vacuo-
lation of late endosomes and endolysosomes. It is thought that
these changes result from decreased membrane fission and con-
comitant interference in endosomal traffic (13, 21). Small-molecule
inhibitors of PIKfyve, all of which have some structural resem-
blance to each other, have been studied as potential drugs for
treating cancer and autoimmune diseases. These inhibitors include
Apilimod (19), Vacuolin-1 (18), a series of 30 Vacuolin-related
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molecules (22), YM201636 (16), and WX8 chemical family mem-
bers (20). Physiological effects of these compounds in cells include
inhibition of autophagy (17, 22, 23), reduced generation of IL-12/
IL-23 (24), and reduced dendritic cell infiltration in psoriasis (25).
Apilimod also inhibits infection by several viruses, including
ZEBOV. Although it does not alter the pH of endosomes nor
inhibit cathepsin B or L (26), Apilimod blocks entry of ZEBOV
and other pathogenic filoviruses (27). Several groups reported
that Apilimod prevents colocalization of VSV-ZEBOV pseu-
doviruses with the ZEBOV endosomal receptor NPC1, but does
not prevent colocalization with early endosomal antigen 1
(EEA1) (5, 27, 28). Apilimod also inhibits entry of pseudotyped
viruses bearing the spike proteins of Middle East respiratory
syndrome CoV, SARS-CoV, and SARS-CoV-2, as well as of
authentic mouse hepatitis virus particles (5).
Here, we have studied the effects of Apilimod on infection of
VSV-eGFP-SARS-CoV-2 and VSV-eGFP-ZEBOV chimeras
and showed that Apilimod blocks infection of both, with a con-
centration that inhibits response by 50% (IC50) of ∼50 nM.
Apilimod and Vacuolin-1 also prevented entry and infection of
VSV-MeGFP-ZEBOV and many of the internalized VSV-MeGFP-
ZEBOV virions colocalized with NPC1 in the distended, vacuolated
endosomes. This suggests that blocking PIKfyve kinase has the same
downstream effects on these viruses, even though VSV-eGFP-
SARS-CoV-2 does not require interaction with NPC1 for membrane
fusion. Apilimod also inhibits infection by authentic SARS-CoV-2
strain 2019-nCoV/USA-WA1/2020 virus, with an IC50 slightly
lower than the IC50 for the VSV-eGFP-SARS-CoV-2. We suggest
that Apilimod, which has passed safety tests in previous hu-
man clinical trials for nonviral indications (24, 25, 29, 30), is a
potential starting point for developing small-molecule entry in-
hibitors of SARS-CoV-2 that could limit infection and disease
pathogenesis.
Results
Apilimod Inhibits Infection of VSV-MeGFP-LCMV and VSV-ZEBOV. We
inoculated SVG-A cells with VSV chimeras expressing the viral
matrix protein (M) fused to eGFP (MeGFP). The chimeras in-
clude VSV (VSV-MeGFP, which initiates fusion at pH < 6.2),
VSV-V269H GP (VSV-MeGFP-V269H, a variant of VSV GP
that initiates fusion at pH < 5.8), rabies virus GP (VSV-MeGFP-
RABV), Lassa virus GP (VSV-MeGFP-LASV), LCMV GP
(VSV-MeGFP-LCMV), or Zaire ebolavirus GP (VSV-MeGFP-
ZEBOV). Following the incubation protocol summarized in Fig.
1A, we tested the effects on infection of Apilimod or Vacuolin-1;
both compounds are small-molecule inhibitors of PIKfyve ki-
nase, which generates PI(5)P and PI(3,5)P2 in late endosomes
and lysosomes. Using a flow cytometry-based assay to monitor a
single round of infection determined by expression of viral














MeGFP fluorescence intensity (a.u.)
VSV-MeGFP-ZEBOV
















** *** *** ******
Fig. 1. Apilimod and Vacuolin-1 inhibit VSV-MeGFP-ZEBOV infection. (A) Schematic of infectivity assay, where SVG-A cells were pretreated for 1 h with 5 μM
Vacuolin, 5 μM Apilimod, 5 μM IN1, or 10 nM BAF A1 and subsequently infected with VSV-MeGFP (MOI = 2), VSV-MeGFP-V269H (MOI = 1), VSV-MeGFP-RABV
(MOI = 0.6), VSV-MeGFP-LASV (MOI = 0.6), VSV-MeGFP-LCMV (MOI = 0.6), or VSV-MeGFP-ZEBOV (MOI = 0.6) for 1 h in the presence of drugs. The cells were
then washed to remove unbound virus and incubated for the indicated times in the presence of drugs. The cells were then fixed, and the percentage of cells
expressing viral MeGFP was measured by flow cytometry. (B) Representative flow cytometry results of an infection assay using VSV-MeGFP-ZEBOV. (C)
Quantification of the infectivity is shown with averages from three independent experiments per condition, each determined as a duplicate measurement
(error bars show SEM). The statistical significance was determined using a one-way ANOVA and Tukey post hoc test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).



















































potently inhibit VSV-MeGFP-ZEBOV infection (Fig. 1C).
These results agree with results obtained by others with Apili-
mod (26, 31) in different cell types infected with murine leuke-
mia virus (MLV) virus pseudotyped with ZEBOV GP or with
Ebola virus itself (26, 27, 32). Apilimod was a less effective in-
hibitor of VSV-MeGFP-LCMV infection, and Vacuolin-1 had
no effect at the concentration used. In contrast, Apilimod and
Vacuolin-1 failed to prevent infection by VSV-MeGFP, VSV-
MeGFP-V269H, VSV-MeGFP-RABV, or VSV-MeGFP-LASV
(Fig. 1C). IN1 (33), an inhibitor of the phosphoinositide kinase
Vps34, the main endosomal generator of PI3P, also interfered
with VSV-MeGFP-LCMV and VSV-MeGFP-ZEBOV infection
(Fig. 1C). All of these viruses require low pH to trigger viral mem-
brane fusion with the endosomal membranes, and, as expected, in-
fection was fully blocked by Bafilomycin A1, which inhibits the
vacuolar type H+-ATPase (V-ATPase) acidification activity (Fig. 1C).
Apilimod and Vacuolin-1 Prevent Cytoplasmic Entry of
VSV-MeGFP-ZEBOV. Productive infection requires delivery of the
viral ribonucleoprotein core (RNP) into the cytosol. In these
A



















































Fig. 2. Apilimod and Vacuolin-1 inhibit VSV-MeGFP-ZEBOV. (A) Schematic of entry assay where SVG-A cells were infected with VSV-MeGFP (MOI = 4),
VSV-MeGFP-V269H (MOI = 4), or VSV-MeGFP-ZEBOV (MOI = 4). Experiments were performed in the presence of 5 μg/mL cycloheximide (CHX) to prevent protein
synthesis. Entry assay was based on the appearance of MeGFP fluorescence on the nuclear margin, on a per cell basis, of fixed infected cells visualized by fluorescence
microscopy. Staining the fixed cells with Alexa647-labeled wheat germ agglutinin identified the plasma membrane of each cell (dashed outlines in C). (B) Virus
infection in the absence of CHX (Left) resulted in the appearance of MeGFP fluorescence throughout the cell volume. The presence of CHX resulted in virus entry
being observed by MeGFP fluorescence at the nuclear margin, which was released from incoming viral particles (Right, white arrows). (Scale bar: 10 μm.) (C) Rep-
resentative examples of maximum-Z projections images from the whole-cell volume obtained with optical sections separated by 0.3 μm using spinning disk confocal
microscopy. MeGFP fluorescence at the nuclear margin released from incoming viral particles is highlighted (white arrows). (Scale bar: 10 μm.) (D) Quantification of the
number of cells with nuclear margin labeling from three independent experiments, each determined from fields containing 59 to 90 cells (error bars show SEM). The
statistical significance of the entry data was analyzed for statistical significance by one-way ANOVA and Tukey post hoc test (***P ≤ 0.001).





























































experiments, we deemed RNP delivery, as monitored by single-cell
fluorescence microscopy imaging (experimental protocol summa-
rized in Figs. 2A and 3A), to be successful when fluorescent
MeGFP encapsulated in the incoming virus appeared at the nu-
clear margin of infected cells. The representative examples of VSV
infection and RNP core release shown in Fig. 2B were obtained in
the absence or presence of cycloheximide, which prevents viral
protein expression. In the absence of cycloheximide (Fig. 2 B,
Left), large amounts of newly synthesized MeGFP are present
throughout the cell. In the presence of cycloheximide (Fig. 2 B,
Right), we observed MeGFP in virions (fluorescent spots) as well as
released MeGFP concentrated at the nuclear margin. We scored
the effect of Apilimod, Vacuolin-1, or IN1 on RNP delivery by
VSV-MeGFP, VSV-MeGFP-V269H, and VSV-MeGFP-ZEBOV
by determining the appearance of MeGFP at the nuclear margin in
cycloheximide-treated cells. Consistent with the infection results,
Apilimod, Vacuolin-1, and IN1 prevented entry of VSV-MeGFP-
ZEBOV but not of VSV-MeGFP or VSV-MeGFP-V269H. As
H VSV-MeGFP VSV-MeGFP-ZEBOVCHX Ap/CHX CHXAp/CHX
Edited
TagRFP-Rab5c












































































































Fig. 3. Endolysosomal traffic of VSV-MeGFP-ZEBOV in cells expressing TagRFP-Rab5c or TagRFP-Rab7a in the presence of Apilimod or Vacuolin-1 (SI Appendix
and Movies S1 and S2). (A) Schematic of live cell imaging experiment using SVG-A cells expressing fluorescently tagged TagRFP-Rab5c or TagRFP-Rab7a. Cells
were infected with VSV-MeGFP, VSV-MeGFP-V269H, or VSV-MeGFP-ZEBOV (MOI = 4). Viruses trafficking (monitored with MeGFP) to the endolysosomal
system (recognized by their labeling with TagRFP-Rab5c or TagRFP-Rab7a) and virus entry (established by MeGFP at the nuclear margin) were ascertained by
live-cell florescence imaging using a spinning disk confocal microscope. (B) Visualization of VSV-MeGFP infection in TagRFP-Rab5c cells in the absence (Left) or
presence (Right, white arrows) of CHX using live-cell imaging. (Scale bar: 10 μm.) (C) Genomic PCR analysis of SVG-A cells showing biallelic integration of
TagRFP into the RAB5C genomic locus by cotransfection of a plasmid coding for Cas9, a linear PCR product coding for the specific guide RNAstargeting a
region near the ATG codon of Rab5c under the control of the U6 promoter, and a template plasmid containing the RFP sequence flanked by 800 base pairs
upstream and downstream of the targeted region (see Materials and Methods for more details) to generate a clonal gene-edited cell line expressing TagRFP-
Rab5c. (D) Quantification of VSV-MeGFP and VSV-MeGFP-ZEBOV colocalization with Rab5c containing endosomes in the presence of CHX together with
absence or presence of 5 μMApilimod depicted in E. Data show number of viruses that colocalized with endosomes containing or not containing Rab5c within
the complete volume of the single cells depicted in E. (E) Representative examples of maximum-Z projection images from four optical sections spaced 0.35 μm
apart of virus entry without or with IN1, Vacuolin, or Apilimod for VSV-MeGFP (Top), VSV-Me-GFP-V269H (Middle), and VSV-MeGFP-ZEBOV (Bottom). Each
condition is in the presence of CHX. All viruses reach Rab5c-containing endosomes, but only VSV-MeGFP-ZEBOV fails to penetrate in the presence of IN1,
Vacuolin-1, or Apilimod. (Scale bars: 10 μm.) Insets correspond to a single optical section. Insets (yellow boxes) correspond to a single optical section. (Scale
bars: 3 μm.) (F) Visualization of VSV infection in TagRFP-Rab7a cells in the absence of CHX (Left) and entry in the presence of CHX (Right, white arrows). (Scale
bar: 10 μm.) (G) Genomic PCR analysis showing biallelic integration of TagRFP into the RAB7A genomic locus to generate a clonal gene-edited cell-line
expressing TagRFP-Rab7a, using the same approach as used for RAB5C. (H) Quantification of VSV-MeGFP and VSV-MeGFP-ZEBOV colocalization with Rab7a
containing endosomes in the presence of CHX with or without 5 μM Apilimod within the complete cell volumes in the images depicted in I. (I) Representative
examples of maximum-Z projection images from four optical sections spaced 0.35 μm apart of virus entry without or with IN1, Vacuolin, or Apilimod for VSV-
MeGFP (Top), VSV-Me-GFP-V269H (Middle), and VSV-MeGFP-ZEBOV (Bottom). All viruses reach Rab7a-containing endosomes, but only VSV-MeGFP-ZEBOV
fails to penetrate in the presence of IN1, Vacuolin-1, or Apilimod. (Scale bars: 10 μm.) Insets correspond to a single optical section. Insets (yellow boxes)
correspond to a single optical section. (Scale bars: 3 μm.)



















































expected, Bafilomycin A1 blocked entry of all viruses (images in
Fig. 2C and quantification in Fig. 2D).
Intracellular Trafficking of Virus Particles in the Presence of Apilimod
or Vacuolin-1. Internalized virus particles traffic along the endo-
cytic pathway to reach the endosomal compartment(s) from
which membrane fusion and genome entry into the cytosol occur.
To establish the identity of the endosomal compartments, we
used genome editing in SVG-A cells (Figs. 3 C and G and 4 B
and D) to replace expression of a subset of proteins enriched in
different endosomal compartments (the small GTPases Rab5c
and Rab7a, EEA1, or NPC1) with their corresponding fluores-
cent chimeras obtained by fusion with TagRFP, mScarlet, or
Halo (Figs. 3 B, E, F, and I and 4 C and E). The lack of fluo-
rescently tagged filipin (a cholesterol binder) in the endolyso-
somal compartment in the absence but not in the presence of
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Fig. 4. Endolysosomal traffic of VSV-MeGFP-ZEBOV in cells expressing NPC1-Halo or coexpressing mScarlet-EEA1 and NPC1-Halo in the presence of Apilimod
(SI Appendix and Movie S3). (A) Schematic of live-cell imaging experiment with gene-edited SVG-A cells expressing NPC1-Halo or NPC1-Halo together with
mScarlet-EEA1. Halo was labeled with either JF549 or JF647. Cells were infected with VSV-MeGFP-ZEBOV (MOI = 3). (B) Genomic PCR analysis showing biallelic
integration of Halo into the NPC1 genomic locus to generate a clonal gene-edited cell line expressing NPC1-Halo, using the same approach as for RAB5C and
RAB7A. (C) Representative examples of maximum-Z projection images from four optical sections spaced 0.25 μm apart in the absence (Left) and presence
(Right) of Apilimod, showing that VSV-MeGFP-ZEBOV reached NPC1-Halo−containing endosomes even in the presence of Apilimod, while failing to penetrate
and infect. (Scale bar: 10 μm.) Insets correspond to a single optical section. (Scale bar: 3 μm.) (D) SVG-A cells with genomic NPC1-Halo were further gene edited
to contain EEA1 tagged with mScarlet. Genomic PCR analysis shows biallelic integration into the EEA1 locus of mScarlet-EEA1 (Left) and into the NPC1 locus of
NPC1-Halo (Right). (E) Representative examples of maximum-Z projection images in the absence (Left) and presence (Right) of Apilimod, showing that
VSV-MeGFP-ZEBOV reached endosomes containing mScarlet-EEA1 and endosomes containing both mScarlet-EEA1 and NPC1-Halo in the presence of Apili-
mod, while failing to penetrate and infect. (Scale bar: 10 μm.) Insets correspond to a single optical section. (Scale bar: 3 μm.) (F) Representative images of
parental cells (Top) and gene-edited SVG-A cells expressing NPC1-Halo (Bottom) incubated with filipin III (naturally fluorescent polyene antibiotic that binds
to cholesterol) in the absence (Left) and presence (Right, NPC1 inhibitor of cholesterol export) of U18666A, showing NPC1-Halo is a functional cholesterol
transporter. (Scale bar: 10 μm.)





























































U18666A, a potent inhibitor of NPC1 (Fig. 4F), showed that
NPC1-Halo remained active as a cholesterol transporter.
Using live-cell spinning disk confocal microscopy (Figs. 3 and
4), we monitored the presence of virus particles in the fluo-
rescently tagged endosomes by colocalization with the fluores-
cent spots from the virus-incorporated MeGFP. We monitored
entry by carrying out the experiments in the presence of cyclo-
heximide, thus ensuring that any MeGFP fluorescent signal at
the nuclear margin originated only from MeGFP molecules
carried by incoming viral particles (Fig. 3 B and F). All cells were
maintained at 37 °C throughout all phases of the experiment to
ensure normal and undisturbed intracellular trafficking. All con-
trol experiments performed in the absence of inhibitors showed
arrival of VSV-MeGFP, VSV-MeGFP-V269H, or VSV-MeGFP-
ZEBOV virus particles to early (Rab5c and EEA1) (Figs. 3E and
4E) or late (Rab7a or NPC1) endosomes and lysosomes (Figs. 3I
and 4 C and E). MeGFP released from all viruses appeared at the
nuclear margin, showing effective RNP release. NPC1, the re-
ceptor for VSV-MeGFP-ZEBOV entry, is required for fusion
from endosomes (2). The successful VSV-MeGFP-ZEBOV in-
fection observed in the absence of drug in cells expressing NPC1-
Halo alone or in combination with mScarlet-EEA1 indicates that
NPC1-Halo is capable of facilitating infection and that VSV-
MeGFP-ZEBOV trafficked to NPC1-Halo−containing endosomes.
Apilimod and Vacuolin-1 treatment of the SVG-A cells led to
enlargement and vacuolization of their endosomes and lyso-
somes tagged with fluorescent EEA1, Rab5c, Rab7a, or NPC1
(Figs. 3–5), in agreement with earlier PIKfyve ablation studies
(13, 21). VSV-MeGFP and VSV-MeGFP-V269H (fluorescent
dots, white) reached all tagged species of enlarged endolyso-
somes and successfully penetrated into the cytosol, as indicated
by MeGFP at the nuclear margin (Fig. 3 E and I). VSV-
MeGFP-ZEBOV also trafficked to all tagged species of en-
larged endolysosomes (Fig. 3 E and I), often reaching one of the
numerous NPC1-containing vacuoles enriched in EEA1 (Figs.
4E and 5 B and C). VSV-MeGFP-ZEBOV in EEA1-containing
endosomes increased in the presence of Apilimod, as also
reported for VLP ZEBOV (27). While able to reach NPC1-
containing functional endosomes in cells treated with Apilimod
(Figs. 4 C and E and 5 B and C), VSV-MeGFP-ZEBOV failed to
penetrate into the cytoplasm, as reflected by absence of MeGFP
in the nuclear margin (Figs. 2C, 3 E and I, 4 C and E, and 5B).
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EEA1 9 11 0 0
EEA1/NPC1 2 3 19 16
NPC1 22 25 23 52
# cells 7 6 4 9
# of endosomes containing VSV-MeGFP-ZEBOV
DMSO Apilimod
Fig. 5. Extent of VSV-MeGFP-ZEBOV traffic into endosomes enriched in NPC1-Halo or NPC1-Halo and mScarlet-EEA1. (A) Schematic of imaging experiment of
VSV-MeGFP-ZEBOV trafficking in NPC1-Halo or NPC1-Halo and mScarlet-EEA1 gene-edited SVG-A cells. (B) Representative examples of maximum-Z projection
images from four optical sections spaced 0.25 μm apart in the absence and presence of Apilimod 2 h or 4 h postinfection. A large number of
VSV-MeGFP-ZEBOV but not of VSV-MeGFP particles accumulated in the endosomes enlarged upon Apilimod treatment. (Scale bar: 10 μm.) (C) Quantification
of VSV-MeGFP-ZEBOV colocalization with mScarlet-EEA1 alone, both mScarlet-EEA1 and NPC1-Halo, or NPC1-Halo alone 2 h and 4 h postinfection, in the
absence or presence of 5 μM Apilimod. Data obtained from complete cell volumes are presented as numbers and corresponding percent colocalizations of
VSV-MeGFP-ZEBOV particles associated with a given type of endosome.



















































Apilimod Blocks Infection of VSV SARS-CoV-2. Using a recombinant
VSV expressing soluble eGFP (VSV-eGFP) where the glycopro-
tein (GP) was replaced with that of ZEBOV GP (VSV-eGFP-
ZEBOV) or SARS-CoV-2 S (VSV-eGFP-SARS-Cov2), we inoc-
ulated MA104 cells with these chimera viruses and tested the ef-
fects of Apilimod on infection by flow cytometry (Fig. 6A). We
found potent inhibition of VSV-eGFP-SARS-CoV-2 infection by
Apilimod and confirmed that the compound also inhibits VSV-
eGFP-ZEBOV infection (Fig. 6B). The dose–response curves
indicated similar effects for VSV-eGFP-ZEBOV and VSV-eGFP-
SARS-CoV-2 (IC50s of ∼50 nM), in contrast to the absence of any
detectable inhibition of VSV-eGFP infection, used here as a
negative control.
Apilimod Blocks Infection of SARS-CoV-2 Virus. To test the effect of
Apilimod on bona fide SARS-CoV-2 infection, we exposed Vero
E6 cells to fully infectious SARS-CoV-2 (strain 2019-nCoV/
USA-WA1/2020); after 24-h incubation, supernatants were har-
vested and titered by focus-forming assay on a separate set of
Vero E6 cells (Fig. 7A). Apilimod strongly inhibited SARS-
CoV-2 infection, and the dose–response curve was similar or more
potent than those observed for VSV-eGFP-ZEBOV or VSV-eGFP-
SARS-CoV-2 (IC50s of ∼10 nM) (Fig. 7B).
Discussion
Coronaviruses, filoviruses, and arenaviruses have different rep-
lication strategies and unrelated surface GPs that engage dif-
ferent receptor molecules during entry (1, 2, 5–8). Coronavirus
and filovirus surface GPs share a requirement for entry-associated
proteolytic processing for activation as fusogens (1). Filoviruses
require passage through low-pH compartments where cathepsins
are active. Coronaviruses may enter directly by fusion at the
plasma membrane or following receptor-mediated endocytosis.
Cell entry of SARS-CoV and SARS-CoV-2 depends on the pro-
tease TMPRSS2 in conjunction with ACE2 (34–37), and, when
TMPRSS2 is present, the entry pathway becomes insensitive to
cathepsin inhibition (34, 37, 38).
The common inhibition of viruses from all three groups by
Apilimod is a consequence of perturbing their shared entry
pathway. Moreover, it is not the cathepsin activity itself that
these compounds affect, judging from the outcome of the assays
with Apilimod and Vacuolin-1 showing they inhibit VSV chi-
meras bearing the surface GPs of ZEBOV and LCMV and, to a
lesser extent, LASV. Apilimod also inhibits infection of cells by
VSV-SARS-CoV-2 as well as by authentic SARS-CoV-2; neither
compound blocks infection by wild-type VSV. For VSV-ZEBOV,
we have shown that the virus reaches a compartment enriched in
NPC1, the ZEBOV coreceptor, and often also enriched in EEA1,
but that it nonetheless fails to release internal proteins into the
cytosol. Apilimod does not inhibit cathepsin (26), but Apilimod
(39) and Vacuolin-1 (17, 23) can interfere with cathepsin matu-
ration, as evidenced by an increase in procathepsin in treated cells;
they do not influence endosomal pH (18, 26, 40), although other
studies report that Apilimod decreases cathepsin activity (41) and
Vacuolin-1 increases pH (17, 23). Irrespective of this discrep-
ancy, both Apilimod and Vacuolin-1 inhibit PIKfyve (17, 19), a
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Fig. 6. Apilimod and Vacuolin-1 inhibit infection of VSV-eGFP-SARS-CoV-2. (A) Schematic of infectivity assay of VSV-eGFP, VSV-eGFP-ZEBOV, and
VSV-eGFP-SARS-CoV-2 in MA104 cells. MA104 cells were pretreated for 1 h with the indicated concentration of Apilimod. Pretreated cells were inoculated
with the indicated virus (MOI = 1) for 1 h at 37 °C. At 6 h postinfection cells were harvested, and the fraction of cell expressing eGFP cells was quantified by
flow cytometry. (B) Quantification of the infectivity is shown with averages ± SEM from three independent experiments. Statistical significance was deter-
mined using a t test (*P ≤ 0.05; **P ≤ 0.01).





























































three-subunit complex (14) with a PI-3P−binding FYVE domain
(10, 11) that recognizes the endosomal marker, PI-3-P. Functional
ablation of this enzyme by genetic means (12, 15) gives rise to the
same cellular phenotype as treatment with either compound
(17–19). The similar dose–response curves for Apilimod inhibition
of the ZEBOV and SARS-CoV-2 chimeras (IC50 of ∼50 nM) and
of authentic SARS-CoV-2 virus (IC50 of ∼10 nM) are in good
agreement with the IC50 of ∼15 nM for Apilimod inhibition of
PIKfyve in vitro (19). Thus, perturbing normal endosomal traf-
ficking by inhibiting PIKfyve activity suggests it is the mechanism
by which Apilimod and Vacuolin-1 block entry of such a diverse
set of viral pathogens.
One of the most striking consequence of PIKfyve inhibition,
and hence of PI-3,5-P2 restriction in endosomal membranes, is
the swelling of endosomes into small, spherical vacuoles—the
phenomenon that gave Vacuolin-1 its name (18). Our imaging
data with VSV-MeGFP-ZEBOV chimeras show that the virus
particles accumulating in these structures, many of which also
contain the NPC1 coreceptor (2, 42), often appear to be rela-
tively immobile and adjacent to the endosomal limiting mem-
brane. One possible explanation is that, when a virion reaches
these distended endosomes, it can bind or remain bound to the
limiting membrane, but not fuse. Another is that virions may fuse
with smaller intraluminal vesicles in the endosomal lumen (43),
but that PI-3,5-P2 depletion prevents back-fusion of these vesi-
cles with the endosomal limiting membrane and inhibits release
into the cytosol of the viral genome.
Inhibition of infection by authentic SARS-CoV-2 shows that
the blocked release of the viral genome from a vacuolated endo-
some is independent of the shape, size, and distribution of spike
protein on the virion. The assay we used to determine effects on
infectivity of authentic virus measured release of virions after
multiple rounds of infection, rather than entry, which we moni-
tored in the VSV-SARS-CoV-2 experiments by detecting eGFP
synthesis in the cytosol. Nevertheless, the IC50 of Apilimod in ex-
periments with authentic virus is remarkably similar to (or even
more potent than) that obtained with chimeric VSV-SARS-CoV-2.
Although cathepsin L inhibitors block SARS-CoV and SARS-
CoV-2 infection in cell culture (4, 5), they have less pronounced
effects when tested in animals (44). This may because another
protease, TMPRSS2 on the surface of cells in relevant tissues,
appears to prime SARS-CoV (44) and SARS-CoV-2 (37) spike
proteins for efficient entry. As the effectiveness of Apilimod and
Vacuolin-1 does not depend on cathepsin inhibition, their ca-
pacity to block entry of several distinct families of viruses is likely
to be independent and downstream of the protease that primes
their surface GP for fusion. Phase I and phase II clinical trials
have shown that Apilimod is safe and well tolerated (24, 25, 29,
30). The trials were discontinued because of lack of effectiveness
against the autoimmune condition for which the drug was tested.
We suggest that one of these compounds, or a potential deriv-
ative, could be a candidate broad-spectrum therapeutic for sev-
eral emerging human viral pathogens, including SARS-CoV-2.
Material and Methods
Cell Culture. Human astroglial SVG-A derived cells (a kind gift from Walter
J. Atwood, Brown University, Providence, RI) were grown at 37 °C and 5%
CO2 in Minimum Essential Medium (MEM) (10-010-CV; Corning) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS, S11150; Atlanta
Biologicals), penicillin, and streptomycin (1406-05-9; VWR International).
African Green Monkey kidney epithelial MA104 cells (a kind gift from Siyuan
Ding, Washington University in St. Louis, St. Louis, MO) were grown at 37 °C
and 5% CO2 in Medium 199 supplemented with 10% heat-inactivated FBS.
Vero C1008 (Vero 76, clone E6, Vero E6) [American Type Culture Collection
(ATCC) CRL-1586] cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FBS, and penicillin and streptomycin. Vero
CCL-81 (ATCC CCL-81) cells were maintained in DMEM supplemented with
10% FBS, 10 mM Hepes pH 7.4, 1% Glutamax, and penicillin/streptomycin.
Reagents. Vacuolin-1 (18) was custom synthesized; Apilimod (HY-14644) was
from MedChem Express, IN1 was a kind gift from N. Gray, Dana-Farber
Cancer Institute and Harvard Medical School, Boston, MA (33), U-18666A
(10009085) and Filipin III (70440) were from Cayman Chemical, Bafilomycin
A1 (B1793-2UG) was from Sigma-Aldrich, Cycloheximide (239764) was from
Calbiochem, and wheat germ agglutinin conjugated with Alexa Fluor-647
(W32466) was from ThermoFisher.
Viruses. Recombinant VSV (Indiana serotype) expressing MeGFP alone which
initiates fusion at pH < 6.2 (VSV-MeGFP) (45) (or in combination with V269H
GP, VSV-MeGFP-V269H), RABV GP (VSV-MeGFP-RABV) (46), LASV GP (VSV-
MeGFP-LASV) (7), LCMV GP (VSV-MeGFP-LCMV), Zaire EBOV GP (VSV-MeGFP-
ZEBOV) (47), or SARS-CoV-2 S Wuhan-Hu-1 strain (VSV-eGFP-SARS-CoV-2—
description to be published elsewhere) were used for infection, entry, and live-
cell imaging assays. All viruses were generated and recovered according to
ref. 48.
SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 was obtained from the
Centers for Disease Control and Prevention (gift of Natalie Thornburg,
Centers for Disease Control, Atlanta, GA). Virus was passaged once in Vero
CCL81 cells (ATCC) and titrated by focus-forming assay also on Vero E6 cells.
Genome Editing. Individual cell lines of SVG-A were gene edited in both al-
leles using the CRISPR-Cas9 system to incorporate fluorescent tags into the N
terminus of Rab5c (TagRFP), Rab7a (TagRFP), EEA1 (mScarlet), or the C ter-
minus of NPC1 (Halo). The NPC1-Halo expressing cells were further gene
edited to incorporate mScarlet-EEA1 creating SVG-A cells simultaneously
expressing mScarlet-EEA1 and NPC1-Halo.
A free PCR strategy (49, 50) was used to generate small guide RNAs (sgRNA)
with target sequences for either Rab5c, Rab7a, NPC1, or EEA1 (Table 1).









































Fig. 7. Apilimod inhibits infection of SARS-CoV-2 virus. (A) Schematic of
infectivity assay of fully infectious Sars-CoV-2 (strain 2019-nCoV/USA-WA1/
2020). Vero E6 cell monolayers were pretreated with medium containing
DMSO or serial dilutions of Apilimod at the indicated concentrations.
SARS-CoV-2 was diluted (MOI = 0.01) in Apilimod-containing medium and
added to Vero E6 cells for 1 h at 37 °C. After adsorption, the viral inocula
were removed, and medium containing the respective concentration of
Apilimod was reapplied. After 24-h incubation, supernatants were harvested
and titrated by focus-forming assay on a separate set of Vero E6 cells. (B)
Quantification of the infectivity is shown with averages ± SEM from three
independent experiments per condition and expressed as the percent in-
fection relative to mock-treated SARS-CoV-2 infected cells.



















































The genomic DNA fragment of Rab5c, Rab7a, NPC1, or EEA1 genes fused
with either TagRFP, Halo, or mScarlet were cloned into the pUC19 vector
(donor constructs) which then served as homologous recombination repair
templates for the Cas9 enzyme-cleaved genomic DNA. Donor constructs
were obtained by a ligation of PCR amplification products from the genomic
DNA fragments, TagRFP, Halo, and mScarlet sequences. Primers F1-R1 and
F3-R3 amplified ∼800 base pairs of genomic sequences upstream and
downstream of the start codon of Rab5c, Rab7a, or EEA1 or the stop codon
of NPC1, respectively (Table 1). Primers F1 and R3 contain sequences com-
plementary to the pUC19 vector linearized using the SmaI restriction en-
zyme (lowercase in the primer sequences). The TagRFP sequence containing
the GGS peptide linker was amplified using primers F2-R2 from a TagRFP
mammalian expression plasmid used as a template. The F2 primer contains
complementary sequences to the 3′ end of the F1-R1 fragment, while the F3
primer contains complementary sequences to the 3′ end of the TagRFP
sequences.
PCR products (fragments F1-R1, F2-R2, and F3-R3) were subjected to
electrophoresis in 1% agarose and gel purified using a purification kit from
Zymogen. The PCR fragments were cloned into the linearized pUC19 vector
using the Gibson Assembly Cloning Kit (E5510S; New England Biolabs).
SVG-A cells (1.5 × 105 cells) were cotransfected with 0.8 μg of Strepto-
coccus pyogenes Cas9, 0.8 μg of free PCR product coding for the target
sgRNA, and 0.8 μg of pUC19 vector using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s instructions. Transfected cells
were grown for 7 d to 10 d and sorted for TagRFP, Halo, or mScarlet ex-
pression using fluorescence-activated cell sorting (FACS) (SH-800S; Sony).
Prior to FACS, NPC1-Halo cells were labeled for 15 min with Janelia Fluor 647
(JF647). Single cells expressing the desired chimera were isolated, clonally
expanded, and then screened by genomic PCR for TagRFP, Halo, or mScarlet
insertion into both alleles (primers listed in Table 2).
Infection Assays. SVG-A cells were plated at about 30 to 40% confluency into
24-well plates and incubated for 1 d at 37 °C and 5% CO2. At the start of the
experiment, cells were incubated with the indicated drug or dimethyl sulf-
oxide (DMSO) at 37 °C for 1 h. Following this, cells were incubated for 1 h at
37 °C with VSV, VSV-MeGFP-V269H, VSV-MeGFP-RABV, VSV-MeGFP-LASV,
VSV-MeGFP-LCMV, or VSV-MeGFP-ZEBOV in drug- or DMSO-containing in-
fection medium (α-MEM, 50 mM Hepes, 2% FBS). Cells were then washed to
remove nonadsorbed viruses and further incubated at 37 °C in medium
containing the drug or DMSO, with experiments ending at the indicated
times by fixation with 3.7% formaldehyde in phosphate-buffered saline
(PBS). Fluorescent intensity from 20,000 single cells from a single round of
Table 1. Primer sequences used to generate the sgRNAs and corresponding genomic fragments
Primer Orientation Nucleotide sequence




Target sequence Rab5c R GACCCGCCATTGCCCGTCCA
Target sequence Rab7a R TCAAACTAAAGGGGGAAAAG
Target sequence NPC1 R TAAATTTCTAGCCCTCTCGC
Target sequence EEA1 R GGTGGTGGTTAAACCATG


























The sgRNAs with target sequences specific for Rab5c, Rab7a, NPC1, or EEA1 were generated using a free PCR strategy using a U6 promoter-containing
primer and reverse primers including Rab5c, Rab7a, NPC1, or EEA1 specific target nucleotide sequences (at the positions indicated with N).
Table 2. Primer sequences used for screening









Primers used for PCR amplification and subsequent DNA sequencing to
verify presence of genome-edited double alleles.





























































infection was determined by flow cytometry using a BD FACSCanto II
equipped with DIVA software package.
MA104 cells were pretreated for 1 h with the indicated concentration of
Apilimod or DMSO. Pretreated cells were inoculated with VSV-eGFP,
VSV-eGFP-ZEBOV, or VSV-eGFP-SARS-CoV-2 at a multiplicity of infection
(MOI) = 1 (based on titers in MA104 cells) in the presence of Apilimod or
DMSO for 1 h at 37 °C. At 6 to 8 h postinfection, cells were collected and
fixed in 2% paraformaldehyde (PFA) and then subjected to flow cytometry.
The percentage of GFP cells was determined using FlowJo software (Tree
Star Industries).
Vero E6 cell monolayers were pretreated for 1 h at 37 °C with serial di-
lutions of Apilimod at the indicated concentrations. Next, SARS-CoV-2 was
diluted to an MOI of 0.01 focus-forming units per cell in Apilimod-containing
medium and added to Vero E6 cells for 1 h at 37 °C. After adsorption, cells
were washed once with PBS, and medium containing the respective con-
centration of Apilimod was added. Cells were incubated for 24 h at 37 °C, at
which time cell culture supernatants were removed and used for determi-
nation of viral titer by focus forming assay.
SARS-CoV-2 Focus-Forming Assay. Cell culture supernatants from virus-
infected cells were diluted serially 10-fold, added to Vero E6 cell mono-
layers in 96-well plates, and incubated at 37 °C for 1 h. Subsequently, cells
were overlaid with 1% (wt/vol) methylcellulose in MEM supplemented with
2% FBS. Plates were harvested 30 h later by removing overlays and fixed
with 4% paraformaldehdye in PBS for 20 min at room temperature. Plates
were washed and sequentially incubated with 1 μg/mL CR3022 anti-spike
antibody (51) and HRP-conjugated goat anti-human IgG in PBS supple-
mented with 0.1% saponin and 0.1% bovine serum albumin (BSA).
SARS-CoV-2−infected cell foci were visualized using TrueBlue peroxidase
substrate (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular
Technologies). Data were processed using Prism software (GraphPad Prism
8.0), and viral titers are reported as percent inhibition relative to mock-
treated SARS-CoV-2−infected cells.
Entry Assay and Intracellular Traffic. SVG-A cells plated on glass #1.5 coverslips
at about 30 to 40% confluency 1 d prior to experiment were treated with
drug or DMSO for 1 h at 37 °C. Following this, cells were incubated at 37 °C
with VSV, VSV-MeGFP-V269H, VSV-MeGFP-RABV, VSV-MeGFP-LASV, VSV-
MeGFP-LCMV, or VSV-MeGFP-ZEBOV in drug- or DMSO-containing infec-
tion medium. After this, cells were washed, then further incubated in me-
dium containing the drug or DMSO at 37 °C, with the experiment ending at
the indicated time by fixation for 20 min at room temperature with 3.7%
formaldehyde in PBS. This was followed with a 10-min incubation of 5 μg/mL
Alexa647-labeled wheat germ agglutinin in PBS to label the outline of
the cells.
Cells were imaged using a spinning disk confocal microscope with optical
planes spaced 0.3 μm apart (52). The entry assay scored the presence of
MeGFP at the nuclear margin in each cell. Trafficking of viruses to endo-
somal compartments was observed using live-cell imaging using the spinning
disk confocal microscope. Chemical fixation tends to eliminate the large
endolysosomal vacuoles generated by Vacuolin-1 or Apilimod and reduces
the colocalization with viral particles contained within. Time series with
images taken every 3 s for 3 min in a single optical plane with the appro-
priate fluorescent channels (52) were acquired from nonfixed samples im-
aged at the end of the experimental period. For experiments containing
NPC1-Halo, the Halo-tagged cells were labeled with either 250 nM JF549
or JF647 dye in media for 30 min at 37 °C. Following labeling, cells were
washed three times with media. The microscope was operated using the
Slidebook 6.4 software package (3I), and images were displayed also using
this software.
Statistical Tests. To compare the means from cells with different treatments,
one-way ANOVA and post hoc Tukey test analysis were used to take into
account unequal sample sizes as indicated in the Figs. 1, 2, and 6 figure
legends.
Data Availability. The VSV virus chimeras are available from the corre-
sponding author S.P.W. upon request.
All study data are included in the article and SI Appendix and Movies
S1–S3.
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